Free Trial

Scinai Immunotherapeutics (SCNI) Competitors

Scinai Immunotherapeutics logo
$0.40 0.00 (0.00%)
Closing price 11/13/2026 03:58 PM Eastern
Extended Trading
$0.42 +0.02 (+5.25%)
As of 11/13/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SCNI vs. REVB, CODX, EVGN, APVO, and HCWB

Should you buy Scinai Immunotherapeutics stock or one of its competitors? Scinai Immunotherapeutics's main competitors and comparable companies include Revelation Biosciences (REVB), Co-Diagnostics (CODX), Evogene (EVGN), Aptevo Therapeutics (APVO), and HCW Biologics (HCWB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scinai Immunotherapeutics compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Revelation Biosciences has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market.

Scinai Immunotherapeutics' return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -124.23% -98.96%
Scinai Immunotherapeutics N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Revelation Biosciences had 8 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 11 mentions for Revelation Biosciences and 3 mentions for Scinai Immunotherapeutics. Scinai Immunotherapeutics' average media sentiment score of 1.94 beat Revelation Biosciences' score of 0.50 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Revelation Biosciences Neutral
Scinai Immunotherapeutics Very Positive

Scinai Immunotherapeutics has higher revenue and earnings than Revelation Biosciences. Revelation Biosciences is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$42.52N/A
Scinai Immunotherapeutics$1.31M0.41-$8.31M$8.660.05

Summary

Scinai Immunotherapeutics beats Revelation Biosciences on 10 of the 11 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Co-Diagnostics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 6.0% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 1.7% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Co-Diagnostics has a consensus target price of $45.00, suggesting a potential upside of 17,301.39%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Scinai Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Co-Diagnostics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

Scinai Immunotherapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 3.16, indicating that its share price is 216% more volatile than the broader market.

Scinai Immunotherapeutics has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scinai Immunotherapeutics$1.31M0.41-$8.31M$8.660.05
Co-Diagnostics$620K4.38-$46.90M-$10.32N/A

In the previous week, Co-Diagnostics had 2 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 5 mentions for Co-Diagnostics and 3 mentions for Scinai Immunotherapeutics. Scinai Immunotherapeutics' average media sentiment score of 1.94 beat Co-Diagnostics' score of 0.76 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Scinai Immunotherapeutics Very Positive
Co-Diagnostics Positive

Scinai Immunotherapeutics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -5,530.54%. Scinai Immunotherapeutics' return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scinai ImmunotherapeuticsN/A N/A N/A
Co-Diagnostics -5,530.54%-322.92%-251.11%

Summary

Scinai Immunotherapeutics beats Co-Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Evogene?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Scinai Immunotherapeutics has higher earnings, but lower revenue than Evogene. Evogene is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scinai Immunotherapeutics$1.31M0.41-$8.31M$8.660.05
Evogene$3.85M0.84-$8.48M-$0.91N/A

Scinai Immunotherapeutics has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Scinai Immunotherapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company Net Margins Return on Equity Return on Assets
Scinai ImmunotherapeuticsN/A N/A N/A
Evogene -694.18%-156.53%-86.80%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Evogene
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Scinai Immunotherapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Evogene has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than Evogene. MarketBeat recorded 3 mentions for Scinai Immunotherapeutics and 2 mentions for Evogene. Scinai Immunotherapeutics' average media sentiment score of 1.94 beat Evogene's score of 0.60 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Scinai Immunotherapeutics Very Positive
Evogene Positive

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.0% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Scinai Immunotherapeutics beats Evogene on 10 of the 13 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Aptevo Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Scinai Immunotherapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -201.49% -119.21%
Scinai Immunotherapeutics N/A N/A N/A

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 0.4% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Aptevo Therapeutics had 3 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 6 mentions for Aptevo Therapeutics and 3 mentions for Scinai Immunotherapeutics. Scinai Immunotherapeutics' average media sentiment score of 1.94 beat Aptevo Therapeutics' score of -0.04 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aptevo Therapeutics Neutral
Scinai Immunotherapeutics Very Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Scinai Immunotherapeutics has higher revenue and earnings than Aptevo Therapeutics. Aptevo Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A
Scinai Immunotherapeutics$1.31M0.41-$8.31M$8.660.05

Aptevo Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market.

Summary

Scinai Immunotherapeutics beats Aptevo Therapeutics on 10 of the 11 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to HCW Biologics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 6.0% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 3,780.48%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts clearly believe HCW Biologics is more favorable than Scinai Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
HCW Biologics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

HCW Biologics has lower revenue, but higher earnings than Scinai Immunotherapeutics. HCW Biologics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scinai Immunotherapeutics$1.31M0.41-$8.31M$8.660.05
HCW Biologics$50K34.63-$7.96M-$27.60N/A

Scinai Immunotherapeutics has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

Scinai Immunotherapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Scinai Immunotherapeutics' return on equity of 0.00% beat HCW Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scinai ImmunotherapeuticsN/A N/A N/A
HCW Biologics -83.03%-262.33%-34.90%

In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than HCW Biologics. MarketBeat recorded 3 mentions for Scinai Immunotherapeutics and 2 mentions for HCW Biologics. Scinai Immunotherapeutics' average media sentiment score of 1.94 beat HCW Biologics' score of 0.89 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Scinai Immunotherapeutics Very Positive
HCW Biologics Positive

Summary

Scinai Immunotherapeutics beats HCW Biologics on 9 of the 16 factors compared between the two stocks.

Get Scinai Immunotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCNI vs. The Competition

MetricScinai ImmunotherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$540K$4.13B$7.89B$12.08B
Dividend YieldN/A3.64%2.47%4.53%
P/E Ratio0.0524.6434.5930.65
Price / Sales0.4116.368.645.80
Price / CashN/A21.8921.0222.32
Price / Book0.054.504.803.95
Net Income-$8.31M-$24.19M$3.52B$391.64M
7 Day Performance-13.49%-4.44%-3.20%-2.48%
1 Month Performance-46.84%-2.06%-1.47%-3.98%
1 Year Performance-95.91%-1.72%1.46%-5.71%

Scinai Immunotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCNI
Scinai Immunotherapeutics
1.3379 of 5 stars
$0.40
flat
N/A-95.9%$540K$1.31M0.0545
REVB
Revelation Biosciences
0.6835 of 5 stars
$3.64
+2.2%
N/A-82.8%$2.49MN/AN/A9
CODX
Co-Diagnostics
2.467 of 5 stars
$0.28
+4.8%
$45.00
+15,971.4%
-97.4%$2.47M$620KN/A115
EVGN
Evogene
0.5951 of 5 stars
$0.28
-14.1%
N/A-69.3%$2.47M$3.85MN/A52
APVO
Aptevo Therapeutics
1.0181 of 5 stars
$1.31
+3.5%
N/A-97.7%$2.38MN/AN/A33

Related Companies and Tools


This page (NASDAQ:SCNI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners